These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 31234588)

  • 1. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
    Cho MM; Song L; Quamine AE; Szewc F; Shi L; Ebben JD; Turicek DP; Kline JM; Burpee DM; Lafeber EO; Phillips MF; Ceas AS; Erbe AK; Capitini CM
    bioRxiv; 2024 Jun; ():. PubMed ID: 37333207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
    Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
    Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.
    de Andrade LF; Smyth MJ; Martinet L
    Immunol Cell Biol; 2014 Mar; 92(3):237-44. PubMed ID: 24343663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.
    Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Sanchez-Correa B; Guerrero B; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Sanchez-Garcia J; Serrano J; Martin C; Duran E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764229
    [No Abstract]   [Full Text] [Related]  

  • 7. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
    Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
    Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of the CD226 Axis in Cancer Immunotherapy.
    Conner M; Hance KW; Yadavilli S; Smothers J; Waight JD
    Front Immunol; 2022; 13():914406. PubMed ID: 35812451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for the immune recognition and selectivity of the immune receptor PVRIG for ligand Nectin-2.
    Hu S; Han P; Wang M; Cao X; Liu H; Zhang S; Zhang S; Liu J; Han Y; Xiao J; Chen Q; Miao K; Qi J; Tan S; Gao GF; Wang H
    Structure; 2024 Jul; 32(7):918-929.e4. PubMed ID: 38626767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
    Sayitoglu EC; Georgoudaki AM; Chrobok M; Ozkazanc D; Josey BJ; Arif M; Kusser K; Hartman M; Chinn TM; Potens R; Pamukcu C; Krueger R; Zhang C; Mardinoglu A; Alici E; Temple HT; Sutlu T; Duru AD
    Front Immunol; 2020; 11():40. PubMed ID: 32082316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the recognition of nectin-like protein-5 by the human-activating immune receptor, DNAM-1.
    Deuss FA; Watson GM; Goodall KJ; Leece I; Chatterjee S; Fu Z; Thaysen-Andersen M; Andrews DM; Rossjohn J; Berry R
    J Biol Chem; 2019 Aug; 294(33):12534-12546. PubMed ID: 31253644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
    Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
    J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia.
    Seel K; Schirrmann RL; Stowitschek D; Ioseliani T; Roiter L; Knierim A; André MC
    Cancer Immunol Immunother; 2024 Jul; 73(9):180. PubMed ID: 38967649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
    Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
    PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.
    Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM
    Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
    Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
    Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential role of CD155 glycosylation in functional binding to DNAM-1 on natural killer cells.
    Tahara S; Okumura G; Matsuo T; Shibuya A; Shibuya K
    Int Immunol; 2024 Apr; 36(6):317-325. PubMed ID: 38289706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.